Analyst Trung Huynh from UBS asked about potential ACIP policy changes ... s focus on operational efficiency, capital allocation, and strategic R&D shifts positions Pfizer to navigate ...

risks related to the successful integration of the licensed asset with Pfizer’s business; disruption from the transaction making it more difficult to maintain business and operational ...

Global pharmaceutical company Pfizer (NYSE:PFE) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling ...

Despite a 6% revenue drop, Pfizer Inc (PFE) focuses on R&D advancements, cost savings, and dividend growth to drive future success.

And the key policy change impacts on Pfizer was a reduced ability to raise ... opportunities to drive improvements in productivity and operational efficiency in our R&D organization, again ...

The guidance does not include the potential impact of future tariffs and trade policy changes ... COVID revenues are declining, Pfizer’s non-COVID operational revenues improved in 2024, driven ...

FDA Commissioner Marty Makary was met with a skeptical set of Senate appropriators Thursday when he testified on his agency’s ...

We recently published a list of the 15 Best High-Yield Dividend Stocks for 2025 and Beyond. In this article, we are going to ...

Artificial intelligence (AI) is at the heart of this change ... Pfizer Inc. (NYSE:PFE) made $63.6 billion in 2024, thanks to robust sales of its non-COVID drugs, which saw an operational growth ...